Erythromelalgia Clinical Trials 2023

Erythromelalgia Clinical Trials 2023

Erythromelalgia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in erythromelalgia clinical trials today.

Erythromelalgia Clinical Trials

Here are the 0 most popular medical studies for erythromelalgia

Popular filter options for erythromelalgia trials

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to erythromelalgia

What are the top hospitals conducting erythromelalgia research?

Erythromelalgia, a rare and debilitating condition characterized by severe burning pain and redness in the extremities, has caught the attention of top medical institutions around the world. Among them is Mayo Clinic in Rochester, renowned for its cutting-edge research and innovative treatments. Though there is currently only one active clinical trial specifically dedicated to erythromelalgia at Mayo Clinic, this trial represents a critical step forward in understanding and finding effective therapies for this challenging disorder. In fact, it marks the first recorded erythromelalgia trial at Mayo Clinic since 2023.

Erythromelalgia affects individuals of all ages but is often misdiagnosed or overlooked due to its rarity. As researchers strive to unravel the mysteries surrounding this condition, conducting trials becomes an essential aspect of advancing knowledge about potential treatment options. By studying how erythromelalgia manifests itself and investigating different therapeutic approaches through rigorous trials, experts hope to improve patients' quality of life while developing more precise diagnostic criteria.

Mayo Clinic's dedication to delving into erythromelalgia underscores their commitment to addressing even the most complex medical challenges faced by patients worldwide. Collaborations among leading specialists in various fields foster an environment conducive to groundbreaking discoveries that may pave new paths towards managing symptoms and eventually finding a cure for erythromelalgia.

Although current efforts may seem modest with just one ongoing trial at Mayo Clinic alone, it serves as a beacon of hope for those affected by this agonizing condition. As scientists continue their tireless pursuit of answers within each carefully designed study protocol, they bring us closer than ever before to unveiling breakthroughs that have significant implications not only for individuals struggling with erythromelalgia but also for future generations facing similar perplexing disorders.

Which are the best cities for erythromelalgia clinical trials?

When it comes to erythromelalgia clinical trials, Rochester, Minnesota is a top destination. With 1 active trial focused on investigating Sequence A and other potential treatments, this city offers individuals suffering from erythromelalgia an opportunity to participate in cutting-edge research aimed at finding effective interventions for this condition.

Which are the top treatments for erythromelalgia being explored in clinical trials?

Clinical trials are uncovering promising treatments for erythromelalgia, a condition characterized by intense burning pain and redness in the extremities. Notably, three top contenders in these trials include:

  • PF-05089771: Currently being explored in two active clinical trials for erythromelalgia.
  • Neridronic acid: Another potential treatment option under investigation with one ongoing trial dedicated to studying its effectiveness.
  • Lidocaine infusion therapy: This innovative approach is also being examined through one clinical trial to determine its efficacy in managing erythromelalgia symptoms. As research progresses, these treatments offer hope for better management of this debilitating condition.
What are the most recent clinical trials for erythromelalgia?

Exciting advancements are being made in the field of erythromelalgia research, as evidenced by recent clinical trials. Among them is Sequence A, a phase 2 trial that holds great promise for individuals living with this debilitating condition. With a focus on understanding the underlying causes and mechanisms of erythromelalgia, this trial seeks to identify potential innovative treatment options to alleviate symptoms and improve quality of life for patients. The availability of such clinical trials serves as a beacon of hope for those affected by erythromelalgia, offering new possibilities for effective management and relief from their symptoms.

What erythromelalgia clinical trials were recently completed?

Recently completed clinical trials have made significant strides in addressing erythromelalgia, a rare and debilitating condition. These trials include the investigation of potential treatments such as medication therapies and interventions to manage symptoms. Although further details on specific trial titles and sponsors are not available at this time, these recent advancements offer hope for individuals living with erythromelalgia by expanding our understanding of the condition and exploring potential avenues for improved care.